Drug Trial Radar · NCT03713879
Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,734
Planned (sponsor's estimate)
Start
Mar 21, 2019
Primary completion
May 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Xijing Hospital; Changhai Hospital; Tianjin Union Medical Center; First Affiliated Hospital of Zhejiang University; Eastern Hepatobiliary Surgery Hospital
- First posted
- Oct 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post ERCP pancreatitis (PEP) occurs in 4 to 5% of patients and is associated with significant morbidities and occasional mortalities. The use of rectall administered indomethacin and pancreatic duct stent (PDS) placement have independently been proven to reduce PEP. The comparative effectiveness of the two methods has however not been studied. It is argued that in the context of indomethacin, the placement of a PDS is unnecessary. Advocates for PDS insertion however believe that mechanical decompression of the pancreatic duct is critical in the prevention of pancreatitis. The investigators propose a multi-centre randomised controlled trial to compare the use of rectal indomethacin to PDS insertion in high risk patients in the prevention of PEP.
Conditions
- Post ERCP Pancreatitis
Interventions
pancreatic stentingDevice
a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025" or .035" wire)
IndomethacinDrug
rectally administered indomethacin before or after ERCP
Primary outcomes
What the sponsor says the trial is designed to measure.
- post-ERCP pancreatitisTime frame: 30 days
- high severity of post-ERCP pancreatitisTime frame: 30 days
- pancreatitis with complicationsTime frame: 30 days
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Endoscopy centre
Xi'an, Shaanxi, China · Recruiting
Eastern Hepatobiliary Surgery Hospital,Endoscopy centre
Shanghai, Shanghai Municipality, China · Recruiting
Endoscopy centre
Shanghai, Shanghai Municipality, China · Not yet recruiting
Endoscopy centre
Tianjin, Tianjin Municipality, China · Recruiting
Endoscopy centre
Hangzhou, Zhejiang, China · Recruiting
Endoscopy Centre, Prince of Wales Hospital
Hong Kong, Hong Kong, Hong Kong · Recruiting
2. Chulalongkorn University and King Chulalongkorn Memorial Hospital
Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.